Lexaria Bioscience (LEXX) Receivables - Net (2016 - 2026)
Lexaria Bioscience's Receivables - Net history spans 12 years, with the latest figure at $42029.0 for Q1 2026.
- On a quarterly basis, Receivables - Net fell 87.31% to $42029.0 in Q1 2026 year-over-year; TTM through Feb 2026 was $42029.0, a 87.31% decrease, with the full-year FY2025 number at $432371.0, up 98.29% from a year prior.
- Receivables - Net hit $42029.0 in Q1 2026 for Lexaria Bioscience, down from $88044.0 in the prior quarter.
- Over the last five years, Receivables - Net for LEXX hit a ceiling of $583290.0 in Q4 2023 and a floor of $42029.0 in Q1 2026.
- Historically, Receivables - Net has averaged $266532.0 across 5 years, with a median of $263491.0 in 2024.
- Biggest five-year swings in Receivables - Net: surged 161.04% in 2024 and later plummeted 87.31% in 2026.
- Tracing LEXX's Receivables - Net over 5 years: stood at $286322.0 in 2022, then surged by 103.72% to $583290.0 in 2023, then crashed by 54.83% to $263491.0 in 2024, then crashed by 66.59% to $88044.0 in 2025, then plummeted by 52.26% to $42029.0 in 2026.
- Business Quant data shows Receivables - Net for LEXX at $42029.0 in Q1 2026, $88044.0 in Q4 2025, and $432371.0 in Q3 2025.